The use of dupilumab in severe atopic dermatitis during pregnancy: a case report

Nabeel H Akhtar; Touraj Khosravi-Hafshejani; Daud Akhtar; Gurbir Dhadwal; Amin Kanani

doi:10.1186/s13223-022-00650-w

The use of dupilumab in severe atopic dermatitis during pregnancy: a case report

Allergy Asthma Clin Immunol. 2022 Feb 3;18(1):9. doi: 10.1186/s13223-022-00650-w.

Authors

Nabeel H Akhtar¹, Touraj Khosravi-Hafshejani², Daud Akhtar³, Gurbir Dhadwal², Amin Kanani⁴

Affiliations

¹ School of Medicine, University College Dublin, Dublin, Ireland.
² Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada.
³ Department of Medicine, University of British Columbia, Vancouver, Canada. dakhtar@alumni.ubc.ca.
⁴ Department of Medicine, Division of Allergy and Immunology, University of British Columbia, Vancouver, Canada.

Abstract

Background: Atopic dermatitis is a common chronic skin disease that can occur in pregnancy. Current treatments include topical and systemic glucocorticoids and cyclosporine. Presently, the only biologic approved for atopic dermatitis is dupilumab with limited data available regarding its safety profile in pregnancy.

Case presentation: We report a case of severe atopic dermatitis treated safely with dupilumab with no adverse maternal or fetal outcomes and resolution of atopic dermatitis postpartum in the absence of maintenance dupilumab therapy.

Conclusion: Here we demonstrate the safe use of dupilumab in pregnancy. Further research is needed to elucidate the role of dupilumab in the management of atopic dermatitis during pregnancy.

Keywords: Atopic dermatitis; Dupilumab; Outcome; Pregnancy.